Literature DB >> 7417958

Malignancy, aggressiveness, and recurrence in giant cell tumor of bone.

N G Sanerkin.   

Abstract

Eighty-six cases of giant cell bone tumor were reviewed with particular attention to frank sarcomatous changes, abnormal mitoses, permeation of vascular channels, and the number of mitoses per square millimeter, and the results were analyzed in relation to malignancy, aggressiveness, and recurrence. There were 4 cases of malignant (Grade III) tumor (about 5%) showing frank sarcomatous changes. Eight (9%) were considered cases of borderline (Grade II+) tumor, without frank sarcomatous changes but showing abnormal mitoses or vascular permeation. Seventy-four (86%) were cases of conventional giant cell tumor (Grades I and II). Mitotic counts did not categorically distinguish the three groups because of overlap. Recurrence essentially reflected the inadequacy of treatment. Metastases were observed only in the malignant group. About a quarter of conventional giant cell tumors were considered aggressive on clinical or radiologic grounds, but these could not be identified on a histologic basis. Tumors with minimal mitotic activity (1/mm2 or less) were almost exclusively nonaggressive. Post-irradiation sarcomas, best regarded as independent new tumors, developed in 4 cases (about 5%).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7417958     DOI: 10.1002/1097-0142(19801001)46:7<1641::aid-cncr2820460725>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  43 in total

1.  Case report 757: Giant cell tumor of rib.

Authors:  R M Hanna; M Kyriakos; S F Quinn
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

2.  Giant cell tumor of the infratemporal fossa.

Authors:  K Gibbons; A Singh; M A Kuriakose; T R Loree; K Harris; A Rubenfeld; S Goodloe; W L Hicks
Journal:  Skull Base Surg       Date:  2000

3.  Treatment and outcome of malignant giant cell tumor in the spine.

Authors:  Huabin Yin; Mo Cheng; Bo Li; Binbin Li; Peng Wang; Tong Meng; Jing Wang; Wang Zhou; Wangjun Yan; Jianru Xiao
Journal:  J Neurooncol       Date:  2015-06-04       Impact factor: 4.130

4.  Treatment and outcome of primary aggressive giant cell tumor in the spine.

Authors:  Huabin Yin; Xinghai Yang; Wei Xu; Binbin Li; Bo Li; Ting Wang; Tong Meng; Peng Wang; Tielong Liu; Wang Zhou; Jianru Xiao
Journal:  Eur Spine J       Date:  2015-01-29       Impact factor: 3.134

5.  In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage.

Authors:  Liang Chen; Xiao-Yi Ding; Chengs-Sheng Wang; Ming-Jue Si; Lian-Jun Du; Wei-Bin Zhang; Yong Lu
Journal:  Radiol Med       Date:  2014-03-07       Impact factor: 3.469

6.  Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone.

Authors:  Charu Chandra Saxena; Rajni Safaya; Neha Kawatra Madan; Shah Alam Khan; Venkateswaran K Iyer
Journal:  J Clin Orthop Trauma       Date:  2015-10-26

7.  Malignant transformation in a fatal case of giant cell tumour of the sacrum.

Authors:  J P Crew; M Flannery; B Manners; C J Coates
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

8.  The value of recognizing suspect diagnoses in the triple diagnosis of giant cell tumor of bone.

Authors:  Mrinalini Kotru; Navjeevan Singh
Journal:  Indian J Orthop       Date:  2007-04       Impact factor: 1.251

9.  [Giant cell tumor of bone with rapid malignant course].

Authors:  M R Lachat; M Weber; M D Cserhati; H P Honegger; A R von Hochstetter
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

10.  Treatment and outcome of giant cell tumors of the pelvis.

Authors:  Maurice Balke; Arne Streitbuerger; Tymoteusz Budny; Marcel Henrichs; Georg Gosheger; Jendrik Hardes
Journal:  Acta Orthop       Date:  2009-10       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.